PlainRecalls
CriticalClass ITerminated

FDA Drug recall · Reported February 21, 2018

Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-602-16.

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore…

Recall #
D-0345-2018
Affected scope
135,277 bottles
Initiated
January 26, 2018
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Primus Pharmaceuticals, Inc. recalled Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus … — a critical-severity action.

Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus … was recalled by Primus Pharmaceuticals, Inc. in February 21, 2018. Reason: Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for …. Check the official notice for the remedy. Verify recall #D-0345-2018 with the FDA Drug before acting.

The recall

Primus Pharmaceuticals, Inc. issued this critical-severity FDA Drug recall — Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for ….

Critical
severity level
Class I
classification
February 21, 2018
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0345-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0345-2018) was formally reported on February 21, 2018, with the manufacturer initiating the action on January 26, 2018. It is classified under Critical severity (Class I), with a current status of Terminated. Primus Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Scottsdale, AZ. Federal records list the affected scope as 135,277 bottles.

The documented reason for this recall is: Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall. Distribution data in the federal record shows the product reached: Nationwide in the USA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category — 14,048 drugs & medications recalls on record

-50005001,0001,5002,000 20052009201220152018202120242026 216

Where this recall sits in the database

Severity2366872097High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.

Severity

Critical

Affected scope

135,277 bottles

Related Recalls

6

5 from same agency

Product description

Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-602-16.

Reason for recall

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Critical (Class I)
Status Terminated
Recall number D-0345-2018
Date reported February 21, 2018
Date initiated January 26, 2018
Recalling firm Primus Pharmaceuticals, Inc.
Firm location Scottsdale, AZ
Affected scope 135,277 bottles
Distribution Nationwide in the USA.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0345-2018) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting — recall details can be updated.
  • This is a Class I (high-risk) recall — stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-602-16.. Recalled by Primus Pharmaceuticals, Inc.. Units affected: 135,277 bottles.
Why was this product recalled?
Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 21, 2018. Severity: Critical. Recall number: D-0345-2018.
Where was the recalled product distributed?
Distribution: Nationwide in the USA..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0345-2018) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with Nicotine Transdermal System Patch, 14 mg, 14 patches per bo… →

Browse all Drugs & Medications recalls →

Data Sources

Source: FDA, CPSC, and NHTSA federal recall databases. This recall: FDA Drug, reported February 21, 2018.

  • Source: FDA — Food and Drug Administration, openFDA Enforcement API (food, drug, and medical device recalls)
  • Source: CPSC — Consumer Product Safety Commission Recalls API (consumer product recalls and hazards)
  • Source: NHTSA — National Highway Traffic Safety Administration Recalls API (vehicle safety recalls)

Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.